Zobrazeno 1 - 10
of 89
pro vyhledávání: '"TAKESHI KOTAKE"'
Autor:
Takashi Kusaka, Shunji Ishiwata, Manami Nishioka, Yuko Okamoto, Masaki Yoshioka, Tomomi Inoue, Takeshi Kotake
Publikováno v:
Heliyon, Vol 10, Iss 15, Pp e35599- (2024)
The antiviral and antibacterial properties of ozone gas have been utilised for air and on-site disinfection. However, excess ozone gas exposure is toxic to humans, necessitating the monitoring of exposure levels. While this has been achieved using oz
Externí odkaz:
https://doaj.org/article/75e09911680147dbb5d7ccbef75976f3
Autor:
Masahiro Takada, Michio Yoshimura, Takeshi Kotake, Kosuke Kawaguchi, Ryuji Uozumi, Masako Kataoka, Hironori Kato, Hiroshi Yoshibayashi, Hirofumi Suwa, Wakako Tsuji, Hiroyasu Yamashiro, Eiji Suzuki, Masae Torii, Yosuke Yamada, Tatsuki Kataoka, Hiroshi Ishiguro, Satoshi Morita, Masakazu Toi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract Radiation therapy (RT) can enhance the abscopal effect of immune checkpoint blockade. This phase I/II study investigated the efficacy and safety of nivolumab plus RT in HER2-negative metastatic breast cancer requiring palliative RT for bone
Externí odkaz:
https://doaj.org/article/7ba1e3013973440cb0f52afdf70ac247
Autor:
Shunji Ishiwata, Taishi Hibino, Tomoe Sakashita, Manami Nishioka, Tomomi Inoue, Takeshi Kotake
Publikováno v:
Heliyon, Vol 9, Iss 2, Pp e13360- (2023)
On-site disinfection techniques are beneficial during a pandemic when there is a marked shortage of personal protective equipment (PPE), as experienced during the coronavirus disease 2019 outbreak. Ozone gas has been considered an alternative on-site
Externí odkaz:
https://doaj.org/article/f89ff18878ff4fdbaae9dd69e9263e28
Autor:
Takeshi Kotake, Yasuki Adachi, Kei Honde, Kanako Tamura, Takaki Sakurai, Jumpei Takeshita, Yumi Amano, Katsuya Juso, Hiroki Izuno, Kazuhiro Yanagihara
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 7, Iss , Pp 100173- (2022)
Pulmonary tumor thrombotic microangiopathy (PTTM) is a fatal cancer-related lung complication. PTTM is difficult to diagnose because of its nonspecific clinical manifestations and imaging findings. Furthermore, no effective treatments currently exist
Externí odkaz:
https://doaj.org/article/8b37212ff31841ab96ac6e220810d31e
Autor:
Yuichiro Kikawa, Takeshi Kotake, Yukiko Kajiwara, Kazuki Hashimoto, Hiroyasu Yamashiro, Shoichiro Ohtani, Shintaro Takao, Masakazu Toi
Publikováno v:
Breast Cancer: Basic and Clinical Research, Vol 13 (2019)
Purpose: To investigate the clinical predictive factors for the efficacy of everolimus (EVE) for advanced/metastatic breast cancer (AMBC). Methods: Routine practice data of consecutive patients with AMBC who received EVE at 5 institutions in western
Externí odkaz:
https://doaj.org/article/dda27a42cb8d4e9b974c7ea971b53a2e
Autor:
Kosuke Kawaguchi, Yurina Maeshima, Hiroshi Ishiguro, Kazuhiko Yamagami, Sachiko Takahara, Hirofumi Suwa, Masae Torii, Shigenori Nagai, Yasuaki Sagara, Wakako Tsuji, Hiroyasu Yamashiro, Takeshi Kotake, Shinji Fukuda, Kuniaki Saito, Yasuko Yamamoto, Masako Kataoka, Yuki Himoto, Atsushi Yonezawa, Yukiko Fukui, Yuki Nakamura, Wei Li, Sunao Tanaka, Satoshi Morita, Masakazu Toi
Publikováno v:
Cancer Research. 83:P2-26
Background: Abemaciclib is a selective CDK4 and CDK6 inhibitor with demonstrated efficacy in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. The most common adverse event across previous trials was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46920a12a9fec6673cb0aad9caebf21d
https://doi.org/10.1158/1538-7445.sabcs22-p2-26-07
https://doi.org/10.1158/1538-7445.sabcs22-p2-26-07
Autor:
Akihito Tsuji, Satoshi Kaihara, Michio Inukai, Takanori Watanabe, Toshihiko Matsumoto, Masahito Kotaka, Hiroki Hashida, Yasuhiro Miyake, Hiroaki Tanioka, Hisateru Yasui, Masato Matsuura, Shinichi Yoshioka, Yoshihiro Okita, Takeshi Kotake, Takahisa Kyogoku, Takeshi Kato, Hironaga Satake
Publikováno v:
The Oncologist
Lessons Learned Background The role of neoadjuvant and adjuvant chemotherapy in the management of initially resectable colorectal cancer liver metastases (CLM) is still unclear. We evaluated the feasibility of 3-month adjuvant treatment with capecita
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15cbf21ed70b73895ef00de1c8f95eb1
http://europepmc.org/articles/PMC8265340
http://europepmc.org/articles/PMC8265340
Autor:
Hiroyasu Yamashiro, Tetsuya Taguchi, Nobuko Ogura, Tomoharu Sugie, Masakazu Toi, Ichiro Nakayama, Hiroshi Ishiguro, Shigeru Tsuyuki, Yuri Fujimoto, Tatsuji Kato, Sachiko Takahara, Hiroshi Yoshibayashi, Masahiro Takada, Tatsuo Kagimura, Yoshio Moriguchi, Kazuhiko Yamagami, Rie Yasuoka, Takeshi Kotake, Hirofumi Suwa, Yuichiro Kikawa, Toshitaka Okuno
Publikováno v:
Cancer Research. 81:PS13-31
BackgroundEribulin (E) is a chemotherapeutic drug that prolongs overall survival (OS) of patients with HER2-negative advanced or metastatic breast cancer (AMBC), mainly in multi-line chemotherapy (ChT) or later. However, the effectiveness and optimal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a344127d16b868c85ad3b61db4f9c11
https://doi.org/10.1158/1538-7445.sabcs20-ps13-31
https://doi.org/10.1158/1538-7445.sabcs20-ps13-31
Autor:
Ryoka Goto, Misa Minami, Hiroko Otake, Takeshi Kotake, Noriaki Nagai, Kazunori Inaba, Mizuki Yamaguchi
Publikováno v:
Chemical and Pharmaceutical Bulletin. 68:1069-1073
Ophthalmic preservatives are indispensable in eye drop formulations, but may be toxic to corneal structures. Corneal damage necessitates the discontinuation of treatment with ophthalmic solutions. Therefore, the development of a new and safe preserva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b1aa2a5c5c3a105b4097bf76ca2779c
https://doi.org/10.1248/cpb.c20-00540
https://doi.org/10.1248/cpb.c20-00540
Autor:
Tatsuki R. Kataoka, Masakazu Toi, Mariko Nishie, Tomoharu Sugie, Moe Tsuda, Takeshi Kotake, Kosuke Kawaguch, Eiji Suzuki, Ayane Yamaguchi, Masahiro Hirata, Masakazu Hattori, Fengling Pu
Publikováno v:
Cancer Immunology, Immunotherapy. 70:817-830
Among several mechanisms for the resistance of human epidermal growth factor receptor 2-overexpressing (HER2 +) cancer cells to trastuzumab, little is known regarding the mechanism underlying the resistance to trastuzumab-mediated antibody-dependent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29061a98a892641e38251b2170ae779c
https://doi.org/10.1007/s00262-020-02732-3
https://doi.org/10.1007/s00262-020-02732-3